Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enobosarm in AR+ TNBC
NCT02368691Phase 2Terminated
- Sponsor
- GTx
- Start
- Jun 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enobosarm in triple-negative breast cancer (TNBC), sponsored by GTx. Primary endpoint: Clinical Benefit Rate at 16 weeks. Started Jun 2015; status: terminated.
02
Drugs
enobosarm
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02368691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02368691.